Noxopharm announces details of changes to its senior executive and Board structures. Dr. Gisela Mautner has been promoted from Global Medical Director to Chief Medical Officer. Dr. Mautner is responsible for the Company's clinical trial activities and strategy. Dr. Olivier Laczka has been appointed as Director of Drug Discovery and Research and is charged with growing the company's drug pipeline, with four programs currently underway. Mr. Greg Ambra has been appointed as Senior Vice-President North American Operations. Mr. Ambra is a U.S. citizen charged with growing the Company's presence in the U.S. His role will be to oversee the growth of the Company's North American clinical trial program, to grow the company's presence and profile within the investment community and pharmaceutical industry, and to assist Dr. Kelly in the company's proposed dual listing in 2020. Dr. Beata Edling has resigned from the Board due to family reasons, effective immediately. The Board will revert to its original 3 directors and defer a replacement until it approaches the company's proposed dual listing in 2020. Dr. Mautner is also an industry advocate and currently holds the role of VP of the Australian association for medical and scientific professionals in the pharmaceutical industry (APPA) which represents approximately 85% of all Medical Affairs professionals in Australia. Greg has over 20 years of experience in the clinical development industry, having held strategic leadership positions in drug/device and CRO companies. Prior to Noxopharm, Greg was the founder and CEO of DZS Clinical Services Inc.